1350 related articles for article (PubMed ID: 28582758)
21. The role of cytokines in the pathogenesis of rheumatoid arthritis.
Feldmann M; Maini RN
Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():3-7. PubMed ID: 10646481
[TBL] [Abstract][Full Text] [Related]
22. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases.
Siebert S; Tsoukas A; Robertson J; McInnes I
Pharmacol Rev; 2015; 67(2):280-309. PubMed ID: 25697599
[TBL] [Abstract][Full Text] [Related]
23. Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents.
Atzeni F; Talotta R; Masala IF; Gerardi MC; Casale R; Sarzi-Puttini P
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):500-510. PubMed ID: 31174819
[TBL] [Abstract][Full Text] [Related]
24. Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes.
Xu H; He Y; Yang X; Liang L; Zhan Z; Ye Y; Yang X; Lian F; Sun L
Rheumatology (Oxford); 2007 Jun; 46(6):920-6. PubMed ID: 17314215
[TBL] [Abstract][Full Text] [Related]
25. In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis.
Ounissi-Benkalha H; Pelletier JP; Tardif G; Mineau F; Jolicoeur FC; Ranger P; Martel-Pelletier J
J Rheumatol; 1996 Jan; 23(1):16-23. PubMed ID: 8838503
[TBL] [Abstract][Full Text] [Related]
26. Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium.
Bramlage CP; Kaps C; Ungethüm U; Bramlage P; Koziolek M; Wessels J; Krenn V; Pruss A; Müller GA; Strutz F; Burmester GR; Häupl T
Scand J Rheumatol; 2008; 37(6):401-9. PubMed ID: 18830904
[TBL] [Abstract][Full Text] [Related]
27. Rheumatoid arthritis: an overview of new and emerging therapies.
Doan T; Massarotti E
J Clin Pharmacol; 2005 Jul; 45(7):751-62. PubMed ID: 15951465
[TBL] [Abstract][Full Text] [Related]
28. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology.
Astorri E; Nerviani A; Bombardieri M; Pitzalis C
Curr Pharm Des; 2015; 21(17):2216-24. PubMed ID: 25760296
[TBL] [Abstract][Full Text] [Related]
29. [Rheumatoid arthritis: current status of therapy].
El Bahri DM; Meddeb N; Sellami S
Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
[TBL] [Abstract][Full Text] [Related]
30. One year in review 2017: pathogenesis of rheumatoid arthritis.
Angelotti F; Parma A; Cafaro G; Capecchi R; Alunno A; Puxeddu I
Clin Exp Rheumatol; 2017; 35(3):368-378. PubMed ID: 28631608
[TBL] [Abstract][Full Text] [Related]
31. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects.
Smolen JS; Redlich K; Zwerina J; Aletaha D; Steiner G; Schett G
Clin Rev Allergy Immunol; 2005 Jun; 28(3):239-48. PubMed ID: 16129908
[TBL] [Abstract][Full Text] [Related]
32. Secukinumab for rheumatology: development and its potential place in therapy.
Koenders MI; van den Berg WB
Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
[TBL] [Abstract][Full Text] [Related]
33. New therapies for rheumatoid arthritis.
Goldblatt F; Isenberg DA
Clin Exp Immunol; 2005 May; 140(2):195-204. PubMed ID: 15807842
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-inducible factor-1 as regulator of angiogenesis in rheumatoid arthritis - therapeutic implications.
Westra J; Molema G; Kallenberg CG
Curr Med Chem; 2010; 17(3):254-63. PubMed ID: 20214567
[TBL] [Abstract][Full Text] [Related]
35. The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation.
Lin YC; Lin YC; Wu CC; Huang MY; Tsai WC; Hung CH; Kuo PL
Oncotarget; 2017 Jan; 8(5):7559-7571. PubMed ID: 27926504
[TBL] [Abstract][Full Text] [Related]
36. [The role of the PD-1 protein in pathogenesis of autoimmune diseases, with particular consideration of rheumatoid arthritis and systemic lupus erythematosus].
Siwiec A; Majdan M
Postepy Hig Med Dosw (Online); 2015 Apr; 69():534-42. PubMed ID: 25983292
[TBL] [Abstract][Full Text] [Related]
37. [Emerging therapy in rheumatoid arthritis].
Kańska U; Boratyński J
Postepy Hig Med Dosw (Online); 2008 Feb; 62():94-102. PubMed ID: 18334924
[TBL] [Abstract][Full Text] [Related]
38. Relative expression and correlation of tumor necrosis factor-α, interferon-γ, and interleukin-17 in the rheumatoid synovium.
Nakajima A; Aoki Y; Sonobe M; Watanabe F; Takahashi H; Saito M; Nakagawa K
Clin Rheumatol; 2016 Jul; 35(7):1691-7. PubMed ID: 27038187
[TBL] [Abstract][Full Text] [Related]
39. Regulatory B cells in rheumatoid arthritis: Alterations in patients receiving anti-TNF therapy.
Bankó Z; Pozsgay J; Gáti T; Rojkovich B; Ujfalussy I; Sármay G
Clin Immunol; 2017 Nov; 184():63-69. PubMed ID: 28506920
[TBL] [Abstract][Full Text] [Related]
40. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy.
Akaogi J; Nozaki T; Satoh M; Yamada H
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):383-94. PubMed ID: 17214584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
